Bharat Book Bureau

Sociable Pharma conducted in-depth primary research in the US and across Europe with seven key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Respiratory Society’s 2011 Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by COPD specialists. http://www.bharatbook.com/detail.asp?id=215243&rt=Chronic-Obstructive-Pulmonary-Disease-COPDKOL-insights-on-treatment-practices-and-unmet-needs.html

Understand key treatment trends based on the latest KOL insights including:

* Step-up approach to the management of COPD
* ULABA: a rival to LAMA therapy?
* LABA versus LAMA therapy: current and future use
market research reports

Identify unmet needs, including

* Managing adherence issues
* Managing patients with very severe COPD
* Treating COPD inflammation
* Management of exacerbations
* Effective treatments for Stage I mild COPD

Table of Contents:

Executive Summary
Scope of Analysis & Methodology
Current Treatment Practice
Inhaled SABA
Inhaled SAMA
Inhaled LABA
Inhaled LAMA
Combination inhaler of ICS/LABA
Phosphodiesterase-4 (PDE-4) inhibitor
Oral corticosteroid
Methylxanthine
Antibiotics
Alpha-1 antitrypsin augmentation therapy
Treatment Challenges / Unmet Needs
COPD Treatment Map

For more information kindly visit :
http://www.bharatbook.com/detail.asp?id=215243&rt=Chronic-Obstructive-Pulmonary-Disease-COPDKOL-insights-on-treatment-practices-and-unmet-needs.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668 / +91 22 27579438
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B

Author :
Print